192 related articles for article (PubMed ID: 24864619)
1. Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations.
Kalra S
J Pak Med Assoc; 2014 Mar; 64(3):359-61. PubMed ID: 24864619
[TBL] [Abstract][Full Text] [Related]
2. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Freeman JS
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S2-6. PubMed ID: 22267300
[TBL] [Abstract][Full Text] [Related]
3. GLP-1R agonist therapy for diabetes: benefits and potential risks.
Samson SL; Garber A
Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
5. Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.
Liakopoulou P; Liakos A; Vasilakou D; Athanasiadou E; Bekiari E; Kazakos K; Tsapas A
Endocrine; 2017 Jun; 56(3):485-494. PubMed ID: 28401444
[TBL] [Abstract][Full Text] [Related]
6. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
7. [Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Suisse; 2014 Aug; 10(439):1549-54. PubMed ID: 25272672
[TBL] [Abstract][Full Text] [Related]
8. New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.
George C; Byun A; Howard-Thompson A
Am J Med; 2018 Nov; 131(11):1304-1306. PubMed ID: 29969616
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
10. Incretin therapy and its effect on body weight in patients with diabetes.
Lind M
Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 as a target for therapeutic intervention.
Rajeev SP; Wilding J
Curr Opin Pharmacol; 2016 Dec; 31():44-49. PubMed ID: 27591964
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.
Deol H; Lekkakou L; Viswanath AK; Pappachan JM
Endocrine; 2017 Jan; 55(1):173-178. PubMed ID: 27696231
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
14. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
Gupta A; Jelinek HF; Al-Aubaidy H
Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
[TBL] [Abstract][Full Text] [Related]
15. The rationale for combining GLP-1 receptor agonists with basal insulin.
Cohen ND; Audehm R; Pretorius E; Kaye J; Chapman LH; Colagiuri S
Med J Aust; 2013 Aug; 199(4):246-9. PubMed ID: 23984780
[TBL] [Abstract][Full Text] [Related]
16. [Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2013 Nov; 68(11):562-8. PubMed ID: 24396969
[TBL] [Abstract][Full Text] [Related]
17. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J
Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
[TBL] [Abstract][Full Text] [Related]
18. Exenatide for the treatment of type 2 diabetes mellitus.
Ruddock B
Issues Emerg Health Technol; 2005 Aug; (71):1-4. PubMed ID: 16389694
[TBL] [Abstract][Full Text] [Related]
19. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
20. Basal insulin or longacting GLP-1 receptor agonists-making the right choice.
Bloomgarden ZT
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):439-41. PubMed ID: 24731676
[No Abstract] [Full Text] [Related]
[Next] [New Search]
